VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.4997
+0.0197 (4.10%)
At close: May 1, 2025, 4:00 PM
0.4800
-0.0197 (-3.94%)
After-hours: May 1, 2025, 5:10 PM EDT
VolitionRx Revenue
In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth. VolitionRx had revenue of $191.66K in the quarter ending December 31, 2024, a decrease of -21.44%.
Revenue (ttm)
$1.23M
Revenue Growth
+59.10%
P/S Ratio
33.67
Revenue / Employee
$14,512
Employees
85
Market Cap
48.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
VNRX News
- 2 days ago - VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - PRNewsWire
- 4 weeks ago - VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update - PRNewsWire
- 4 weeks ago - Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 - PRNewsWire
- 5 weeks ago - Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 - PRNewsWire
- 5 weeks ago - VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering - PRNewsWire
- 5 weeks ago - VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update - PRNewsWire
- 5 weeks ago - Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry - PRNewsWire